Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Stage IV Soft Tissue Sarcoma
NCT03121846Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in soft tissue sarcoma (STS), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03121846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121846.